KORUS FTA Negotiations

Text of the KORUS FTA

Government Documents

CPTech Comments

NGO Documents

Academic Documents

Industry Comments

  • Misc.

    News Stories

    Royalty Guidelines

    Earlier Documents from Ongoing Trade Disputes on Drug Pricing in Korea

    Legislation for the Export of Pharmaceutical Products Produced Under Compulsory License

    Compulsory Licensing Dispute of Glivec

    On January 30, 2002, the People's Health Coalition for Equitable Society, the Association of Physicians for Humanism, and the Korean Pharmacists for Democratic Society jointly filed for a compulsory license for Glivec. This is a drug that has been highly successful in treating chronic myelogenous leukemia (CML), and a stomach cancer called gastrointestinal stromal tumor (GIST). Norvartis sets the Korean price according to the price in seven high-income countries, so the drug is priced out of reach for most Koreans.

    Half a year earlier, US Secretary of Commerce Donald Evans, had written the Korean Ministers of Health and Trade, threatening a "serious trade dispute" over drug pricing. The request for a compulsory license was quickly denied.

    Return to: CPTech Home -> Main IP Page -> IP and Healthcare